FDA Clears Once-Daily Bixlenvo for Suppressed HIV
Federal regulators have given the green light to a new once-daily treatment option for specific adults managing HIV.
The U.S. Food and Drug Administration approved Gilead Sciences’ oral combination pill, branded as Bixlenvo, on August 27. The regulatory decision specifically targets adults whose HIV infection has already been reduced to very low levels. For patients with suppressed viral loads who cannot use other regimens, the decision provides a fresh therapeutic pathway.
Inside the Dual-Drug Tablet
Reuters reports that Bixlenvo combines two distinct HIV medicines: bictegravir and lenacapavir.
It features a high barrier to resistance, serving as a key component of Gilead’s existing blockbuster treatment Biktarvy.
The human immunodeficiency virus attacks the body’s immune system. Without treatment, it can progress to acquired immunodeficiency syndrome, commonly known as AIDS. There is currently no effective cure for the virus.
Familiar Components in a New Combination
According to Reuters reporting, the drug is marketed as Sunlenca for HIV treatment and as Yeztugo for HIV prevention. The combination of bictegravir and lenacapavir into a single daily tablet provides a new therapeutic pathway for patients requiring customized management strategies after achieving viral suppression.
Related reading